1. Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
- Author
-
Fadul A, Abdalla E, Mohamed A, Ali B, Elamin N, Alsayed AA, Al-Mashdali AF, Singh K, and Mohamed SF
- Subjects
vitamin b12 ,myeloproliferative neoplasms (mpns) ,chronic myeloid leukemia (cml) ,polycythemia vera (pv) ,essential thrombocythemia (et) ,and myelofibrosis (mf). ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abdalla Fadul,1 Elmustafa Abdalla,1 Anas Mohamed,1 Bashir Ali,1 Nusiba Elamin,1 Ahmed Abdelghafar Alsayed,1 Abdulrahman F Al-Mashdali,2 Kalpana Singh,3 Shehab F Mohamed2 1Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar; 2Department of Hematology, Hamad Medical Corporation, Doha, Qatar; 3Department of medical biostatistics, Hamad Medical Corporation, Doha, QatarCorrespondence: Abdalla Fadul, Department of Internal Medicine, Hamad Medical Corporation, Al-Rayyan Road, PO Box 3050, Doha, Qatar, Tel +97477999443, Fax +97444397857, Email aabdu69044@gmail.comBackground: Elevated vitamin B12 (B12) levels are linked to an increased risk of cancers, including hematological malignancies. This study focuses on the relationship between elevated B12 and myeloproliferative neoplasms (MPNs): Polycythemia Vera (PV), Primary Myelofibrosis (MF), Essential Thrombocytosis (ET), and Chronic Myeloid Leukemia (CML). Elevated B12 in MPNs is believed to arise from increased transcobalamin I (TCI) secretion by proliferating leukocytes, leading to higher serum levels. B12 may serve as a diagnostic and prognostic biomarker for these conditions. However, its sensitivity, specificity, and cutoff levels are unclear.Aim: To assess the prevalence of high B12 levels in MPN patients, determine the median levels, identify a diagnostic cutoff, and evaluate the sensitivity and specificity of B12 as a marker.Methods: Data were retrieved from the National Center for Cancer Care and Research in Doha, Qatar, for MPN patients from January 2016 to December 2022.Results: A total of 467 patients were included: 232 with CML, 98 with PV, 88 with ET, and 50 with MF. The majority were male (66%) and of Asian origin (56%), with a median age of 48.7 years. CBC results showed median hemoglobin of 9.2 g/dL, WBC count of 73 x 10^3/uL, and platelet count of 531 x 10^3/uL. Elevated B12 levels were found in 95 patients (20%): 71% CML, 14% PV, 10% MF, and 5% ET. Extreme elevations were seen in 59 patients. The mean B12 level decreased from 747.3 ± 686.5 pg/mL before treatment to 397.9 ± 343.7 pg/mL after one year (p=0.01). Median levels were 458 pg/mL (718) before treatment and 301 pg/mL (229) after. In the extreme high B12 group, the mean was 1722 pg/mL before and 677 pg/mL after treatment.Conclusion: Elevated B12 levels are associated with disease activity in CML. However, their role as a reliable marker for disease monitoring remains uncertain, and further studies are needed to confirm their utility for CML progression.Keywords: Vitamin B12, myeloproliferative neoplasms, MPNs, chronic myeloid leukemia, CML, polycythemia vera, PV, essential thrombocythemia, ET, myelofibrosis, MF
- Published
- 2024